Mayne enters US women’s health market with NASDAQ-listed partner for $205m; shareholders spooked

Mon 05 Dec 22, 11:19am (AEST)
An individual retrieves a selection of Australian one hundred dollar notes from a checkered wallet
Source: iStock

Key Points

  • Mayne Pharma has signed a licence agreement with NASDAQ-listed TherapeuticsMD to sell five women’s health products in US
  • Deal sees Mayne paying TherapeuticsMD A$205.5m; further performance payments due to TherapeuticsMD
  • Products’ revenues in Q3 CY2022 stand at A$30.6m revenue; gross profit A$25.1m

In a deal the company expects to be immediately material to its own revenues and profits, Australia’s Mayne Pharma (ASX:MYX) is entering the US women’s healthcare product market with NASDAQ-listed partner TherapeuticsMD. 

Executing a licencing agreement with Therapeutics, Mayne will hand the former $205.5m to fund the product-line acquisition.

Payments to Therapeutics MD by Mayne will be made on sales-based milestones; for every US$100m in revenue made each year, Mayne will need to hand TherapeuticsMD $5m. 

Mayne will also pay royalties of US$3m a year for 12 years. 

Onerous obligations scare shareholders 

Perhaps unsurprisingly, some shareholders have seen it fit to scatter. Maybe Pharma shares are down -8% in the early second hour of trade. 

The US$140m acquisition will be funded in part “through a binding commitment from Rubric Capital Management for approximately US$27.95m…the maximum number of shares issued to Rubric will be the lesser of 178.8m shares and 9.61% of Mayne Pharma’s issued capital.” 

Mayne will now sell five products already on the shelves in the US with the company expecting material impact on revenue and profits to be immediate. 

Across the five products Mayne today acquires a licence for, Q3 CY2022 profits from those items alone stood at $25.1m. The currently weaker Australian dollar against the greenback is also a strong point of today’s deal. 

What will Mayne Pharma be selling? 

Mayne Pharma picks up the licence for the following products: 

  • BIJUVA - A menopause treatment to treat hot flushes (licence until 2032)

  • IMVEXXY - Another menopause treatment used to treat vaginal pain (licence until 2034)

  • ANNOVERA - A long-term self-insertable contraceptive product (licence until 2039)

  • BocaGreenMD - Prenatal vitamins emphasising natural ingredients 

  • VitaMedMD - Prenatal vitamins 

Mayne expects the deal to close by the end of the calendar year. 

Is Mayne's global strategy coming on too thick and fast for investors? Pictured: Mayne's three month charts
Is Mayne's global strategy coming on too thick and fast for investors? Pictured: Mayne's three month charts


Written By

Jonathon Davidson

Finance Writer

Jonathon is a journalism graduate and avid market watcher with exposure to governance, NGO and mining environments. He was most recently hired as an oil and gas specialist for a trade publication.

Get the latest news and insights direct to your inbox

Subscribe free